Kornitzer Capital Management Inc. KS Sells 57,850 Shares of Natera, Inc. (NASDAQ:NTRA)

Kornitzer Capital Management Inc. KS lessened its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 35.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 106,119 shares of the medical research company's stock after selling 57,850 shares during the period. Kornitzer Capital Management Inc. KS owned about 0.08% of Natera worth $16,799,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of NTRA. Blue Trust Inc. grew its holdings in Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after purchasing an additional 97 shares during the period. Versant Capital Management Inc lifted its position in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after buying an additional 166 shares during the last quarter. Covestor Ltd boosted its stake in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company's stock worth $47,000 after acquiring an additional 95 shares during the period. Principal Securities Inc. increased its holdings in shares of Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after acquiring an additional 59 shares during the last quarter. Finally, True Wealth Design LLC bought a new stake in Natera in the 3rd quarter valued at $57,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of research analyst reports. JPMorgan Chase & Co. lifted their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, December 13th. Barclays initiated coverage on shares of Natera in a report on Thursday, January 23rd. They set an "overweight" rating and a $200.00 target price for the company. Sanford C. Bernstein increased their price target on shares of Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a report on Friday, January 10th. Guggenheim raised their price objective on shares of Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a research report on Friday, January 17th. Finally, Canaccord Genuity Group upped their target price on Natera from $165.00 to $180.00 and gave the company a "buy" rating in a research report on Friday, January 3rd. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $170.94.

Natera Price Performance

Natera stock traded down $5.88 during trading hours on Friday, reaching $162.31. 1,604,242 shares of the stock were exchanged, compared to its average volume of 1,342,687. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a twelve month low of $69.74 and a twelve month high of $183.00. The company has a market cap of $21.43 billion, a P/E ratio of -92.22 and a beta of 1.66. The stock has a 50 day moving average of $167.98 and a two-hundred day moving average of $145.23.

Insider Buying and Selling

In other Natera news, CEO Steven Leonard Chapman sold 78,553 shares of the firm's stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41. Following the sale, the chief executive officer now owns 267,629 shares of the company's stock, valued at approximately $44,150,756.13. This trade represents a 22.69 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider John Fesko sold 669 shares of the business's stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $159.60, for a total value of $106,772.40. Following the transaction, the insider now directly owns 114,142 shares of the company's stock, valued at $18,217,063.20. This trade represents a 0.58 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 295,772 shares of company stock worth $49,741,699. Corporate insiders own 7.60% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.